ASH Conference 2023 explores ways to extend su... - CLL Support
ASH Conference 2023 explores ways to extend survival for those with CLL
You need to be a member of this community to see this post.
Read more about...
6 Replies
You need to be a member of this community to see hidden responses.
Not what you're looking for?
You may also like...
Ibrutinib combinations in CLL therapy: scientific rationale and clinical results
From Blood Cancer Journal 29th April 2021
Four strategies have been tested in recent years...
Measurable residual disease (MRD) status predicts Progression Free Survival (PFS) for patients with Chronic Lymphocytic Leukemia (CLL)
Measurable residual disease (MRD) refers to the presence of disease at low levels not detected...
Alterations of the immune system caused by CLL B‐cells
Abstract: Here, we review the current understanding of the underlying interplay between the...
Advances in Targeted Therapy for R/R CLL OncLive videos & transcripts by Nirav Shah MD & Nicole Lamanna MD
Advances in Targeted Therapy for R/R CLL
(These OncLive presentations are intended for medical...
Improving Treatment Options for Patients with Double Refractory CLL - patients who progressed after treatment with both cBTKis and BCL2i
Abstract
The proliferation and survival of chronic lymphocytic leukemia...
Related Posts
- Can Venetoclax/Obinituzimab reduce the risk of additional somatic mutations? - Not necessarily. The BTK inhibitors are excellent at....
BTK inhibitors for the treatment of CLL - the current state of play of 'brutinibs'- OncLive 9 CLL Videos - Optimizing the Treatment of CLL With Novel Therapies and more Take-home messages from ASH 2021
- CLL survival times ARE improving, thanks to BTK and BCL-2 inhibitors
- BTK Degrader Shows Potential for Treating Refractory CLL and SLL
